Neuroglial roots of neurodegenerative diseases: Therapeutic potential of palmitoylethanolamide in models of alzheimer's disease

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 1, 2013, Pages 62-69

  Scuderi, Caterina ^a   Steardo, Luca ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer's disease; Astrocytes; Beta amyloid; Hippocampal organotypic cultures; Neuroinflammation; Neurons; Palmitoylethanolamide; Peroxisome proliferator activated receptor

Indexed keywords

AMYLOID BETA PROTEIN; CYCLOOXYGENASE 2; CYTOKINE; GLIAL FIBRILLARY ACIDIC PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PROSTAGLANDIN E2; PROTEIN S100B;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; CELL VIABILITY; CONTROLLED STUDY; DENSITOMETRY; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOFLUORESCENCE TEST; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NISSL STAINING; NONHUMAN; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ALZHEIMER DISEASE; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; ETHANOLAMINES; HIPPOCAMPUS; NEURODEGENERATIVE DISEASES; NEUROGLIA; ORGAN CULTURE TECHNIQUES; PALMITIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84875299884     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527311312010011     Document Type: Article

References (53)

1. Jicha, G.A.; Carr, S.A. Conceptual evolution in Alzheimer's disease: implications for understanding the clinical phenotype of progressive neurodegenerative disease. J. Alzheimer's Dis., 2010, 19(1), 253-272.
2. Querfurth, H.W.; LaFerla, F.M. Alzheimer's disease. N. Engl. J. Med., 2010, 362(4), 329-344.
3. Blennow, K.; de Leon, M.J.; Zetterberg, H. Alzheimer's disease. Lancet., 2006, 368(9533), 387-403.
4. Bertram, L.; Tanzi, R.E. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat. Rev. Neurosci., 2008, 9(10), 768-778.
5. Dhawan, V.; Eidelberg, D. Mom and me: brain metabolism links Alzheimer disease to maternal genes. Neurology., 2009, 72(6), 486-487.
6. Huang, H.C.; Jiang, Z.F. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. J. Alzheimers Dis., 2009, 16(1), 15-27.
7. Welsh-Bohmer, K.A.; White, C.L. Alzheimer disease: what changes in the brain cause dementia? Neurology., 2009, 72(4), e21.
8. LaFerla, F.M.; Green, K.N.; Oddo, S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci., 2007, 8(7), 499-509.
9. Tuppo, E.E; Arias, H.R. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell. Biol, 2005, 37(2), 289-305.
10. Mrak, R.E.; Griffin, W.S. The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease. Neurobiol. Aging., 2001, 22(6), 915-922.
11. Zhang, D.; Hu, X.; Qian, L.; O'Callaghan, J.P.; Hong, J.S. Astrogliosis in CNS Pathologies: Is There A Role for Microglia? Mol. Neurobiol, 2010, 41(2-3), 232-234.
12. Scuderi, C; Esposito, G.; Blasio, A.; Valenza, M.; Arietti, P.; Steardo, L. Jr; Carnuccio, R.; De Filippis, D.; Petrosino, S.; Iuvone, T.; Di Marzo, V.; Steardo, L. Palmitoylethanolamide counteracts reactive astrogliosis induced by p-amyloid peptide. J. Cell. Mol. Med, 2011, 15(12), 2664-2674.
13. Heneka, M.T.; Rodríguez, J.J.; Verkhratsky, A. Neuroglia in neurodegeneration. Brain Res. Rev., 2010, 63(1-2), 189-211.
14. Steinman, L. Nuanced roles of cytokines in three major human brain disorders. J. Clin. Invest., 2008, 118(11), 3557-3563.
15. Fuller, S., Steele, M.; Münch, G. Activated astroglia during chronic inflammation in Alzheimer's disease--do they neglect their neurosupportive roles? Mutat. Res., 2010, 690(1-2), 40-49.
16. Bélanger, M; Magistretti, P.J. The role of astroglia in neuroprotection. Dialogues Clin. Neurosci., 2009, 11(3), 281-295.
17. Cowley, T.R.; O'Sullivan, J.; Blau, C.; Deighan, B.F.; Jones, R.; Kerskens, C.; Richardson, J.C.; Virley, D.; Upton, N.; Lynch, M.A. Rosiglitazone attenuates the age-related changes in astrocytosis and the deficit in LTP. Neurobiol. Aging., 2012, 33(1), 162-175.
18. Cadas, H.; Schinelli, S.; Piomelli, D. Membrane localization of N-acylphosphatidylethonolamine in central neurons: studies with exogenous phospholipases. J. Lipid Mediat. Cell. Signal., 1996, 14(1-3), 63-70.
19. Hansen, H.S.; Moesgaard, B.; Hansen, H.H.; Petersen, G. N-Acylethanolamines and precursor phospholipids: relation to cell injury. Chem. Phys. Lipids., 2000, 108(1-2), 135-150.
20. Walter, L.; Franklin, A.; Witting, A.; Moller, T.; Stella, N. Astrocytes in culture produce anandamide and other acylethanolamides. J. Biol. Chem., 2002, 277(23), 20869-20876.
21. Muccioli, G.G.; Stella, N. Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology., 2008, 54(1),16-22.
22. Mazzari, S.; Canella, R.; Petrelli, L.; Marcolongo, G.; Leon, A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol., 1996, 300(3), 227-236.
23. Skaper, S.D.; Buriani, A.; Dal Toso, R.; Petrelli, L.; Romanello, S.; Facci, L.; Leon, A. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. U. S. A., 1996, 93(9), 3984-3989.
24. Calignano, A.; La Rana, G.; Giuffrida, A.; Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature., 1998, 394(6690), 277-281.
25. Calignano, A.; La Rana, G.; Piomelli, D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur. J. Pharmacol., 2001, 419(2-3), 191-198.
26. Lambert, D.M.; Vandevoorde, S.; Diependaele, G.; Govaerts, S.J.; Robert, A.R. Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia., 2001, 42(3), 321-327.
27. Franklin, A.; Parmentier-Batteur, S.; Walter, L.; Greenberg, D.A.; Stella, N. J. Neurosci., 2003, 23(21), 7767-7775.
28. Jaggar, S.I.; Hasnie, F.S.; Sellaturay, S.; Rice, A.S. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain., 1998, 76(1-2), 189-199.
29. Sheerin, A.H.; Zhang, X.; Saucier, D.M.; Corcoran, M.E. Selective antiepileptic effects of N-palmitoylethanolam ide, a putative endocannabinoid. Epilepsia., 2004, 45(10), 1184-1188.
30. Hansen, H.S.; Diep, T.A. N-acylethanolamines, anandamide and food intake. Biochem. Pharmacol., 2009, 78(6), 553-560.
31. Capasso, R.; Izzo, A.A.; Fezza, F.; Pinto, A.; Capasso, F.; Mascolo, N.; Di Marzo, V. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br. J. Pharmacol., 2001, 134(5), 945-950.
32. De Petrocellis, L., Bisogno, T.; Ligresti, A.; Bifulco, M.; Melck, D.; Di Marzo, V. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam. Clin. Pharmacol., 2002, 16(4), 297-302.
33. Di Marzo, V.; Melck, D.; Orlando, P.; Bisogno, T.; Zagoory, O.; Bifulco, M.; Vogel, Z.; De Petrocellis, L. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J., 2001, 358(Pt 1), 249-255.
34. Bouchard, J.F.; Lépicier, P.; Lamontagne, D. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci., 2003, 72(16), 1859-1870.
35. Lo Verme, J.; Fu, J; Astarita, G.; La Rana, G.; Russo, R.; Calignano, A.; Piomelli, D. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol, 2005, 67(1), 15-19.
36. Lo Verme, J.; Russo, R.; La Rana, G; Fu, J; Farthing, J.; Mattace-Raso, G; Meli, R.; Hohmann, A; Calignano, A.; Piomelli, D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J. Pharmacol. Exp. Ther, 2006, 319(3), 1051-1061.
37. Re, G.; Barbero, R.; Miolo, A; Di Marzo, V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet. J., 2007, 173(1), 21-30.
38. Kummer, M.P.; Heneka, M.T. PPARs in Alzheimer's disease. PPAR Res., 2008, 403-896.
39. Wanger, K.D.; Wanger, N. Peroxisome proliferator-activated receptor beta/delta (PPARp/8) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol. Ther., 2010, 125(3), 425-435.
40. Landreth, G; Jiang, Q.; Mandrekar, S.; Heneka, M. PPAR gamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics., 2008, 5(3), 481-489.
41. Scuderi, C; Valenza, M.; Stecca, C; Esposito, G; Carratù, M.R.; Steardo, L. Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α. J. Neuroinflammation., 2012, 9,49.
42. D'Agostino, G.; Russo, R.; Avagliano, C; Cristiano, C; Meli, R; Calignano, A. Palmitoylethanolamide Protects Against the Amyloid- p25-35-Induced Learning and Memory Impairment in Mice, an ExperimentalModelofAlzheimerDisease. Neuropsychopharmacology., 2012, 37(7), 1784-1792.
43. Genovese, T.; Esposito, E.; Mazzon, E.; Di Paola, R.; Meli, R; Bramanti, P.; Piomelli, D.; Calignano, A.; Cuzzocrea, S. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J. Pharmacol. Exp. Ther., 2008, 326(1), 12-23.
44. Hansen, H.S. Palmitoylethanolamide and other anandamide congeners: proposed role in the diseased brain. Exp. Neurol, 2010, 224(1), 48-55.
45. Pellegrini-Giampietro, D.E.; Cozzi, A.; Peruginelli, F.; Leonardi, P.; Meli, E.; Pellicciari, R.; Moroni, F. 1-Aminoindan-1,5-dicarboxylic acid and (S)-(+)-2-(3'-carboxybicyclo[1,1,1]pentyl)-glycine, two mGlu1 receptor-preferring antagonists, reduce neuronal death in vitro and in vivo models of cerebral ischemia Eur. J. Neurosci., 1999, 11(10), 3637-3647.
46. Repetto, G.; del Peso, A; Zurita, J.L. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc, 2008, 3(7): 1125-1131.
47. Goedert, M.; Spillantini, M.G A century of Alzheimer's disease. Science., 2006, 314(5800), 777-781.
48. Craft, J.M.; Watterson, D.M.; Van Eldik, L.J. Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration. Glia., 2006, 53(5), 484-490.
49. Selkoe, D.J. Amyloid beta-protein and the genetics of Alzheimer's disease. J. Biol. Chem., 1996, 271(31), 18295-18298.
50. Parpura, V.; Heneka, M.T.; Montana, V.; Oliet, S.H.; Schousboe, A; Haydon, P.G.; Stout, R.F.; Spray, D.C.; Reichenbach, A; Pannicke, T.; Pekny, M.; Pekna, M.; Zorec, R; Verkhratsky, A. Glial cells in (pathophysiology. J. Neurochem., 2012, 121(1), 4-27.
51. Verkhratsky, A.; Olabarria, M.; Noristani, H.N.; Yeh, C.Y.; Rodriguez, J.J. Astrocytes in Alzheimer's disease. Neurotherapeutics., 2010, 7(4), 399-412.
52. Esposito, G.; Scuderi, C; Lu, J; Savani, C; De Filippis, D.; Iuvone, T.; Steardo, L. Jr, Sheen, V.; Steardo, L. S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. J. Cell. Mol. Med, 2008, 12(3), 914-927.
53. Naert, G; Rivest, S. The role of microglial cell subsets in Alzheimer's disease. Curr. Alzheimer. Res., 2011, 8(2), 151-155.